Clinical Features and Vaccination Effects among Children with Post-Acute Sequelae of COVID-19 in Taiwan

Yu Lung Hsu, Pei Chi Chen, Yi Fen Tsai, Chi Hung Wei, Lawrence Shi Hsin Wu, Kai Sheng Hsieh, Miao Hsi Hsieh, Huan Cheng Lai, Chien Heng Lin, Hsiao Chuan Lin, Chieh Ho Chen, An Chyi Chen, Hung Chih Lin, I. Ching Chou, Wen Jue Soong, Kao Pin Hwang, Henry Horng Shing Lu, Ruby Pawankar, Hui Ju Tsai, Jiu Yao Wang

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Post-acute sequelae of SARS-CoV-2 infection (PASC) affects patients after recovering from acute coronavirus disease 2019 (COVID-19). This study investigates the impact of SARS-CoV-2 vaccination on PASC symptoms in children in Taiwan during the Omicron pandemic. Methods: We enrolled children under 18 years with PASC symptoms persisting for more than 4 weeks. Data collected included demographics, clinical information, vaccination status, and symptom persistence. We used logistic regression models to compare symptoms in the acute and post-COVID-19 phases and to assess the association between vaccination and these symptoms. Results: Among 500 PASC children, 292 (58.4%) were vaccinated, 282 (52.8%) were male, and the mean (SD) age was 7.6 (4.6) years. Vaccinated individuals exhibited higher odds of experiencing symptoms in the previous acute phase, such as cough (adjusted odds ratio [AOR] = 1.57; 95% confidence interval [CI]: 1.02–2.42), rhinorrhea/nasal congestion (AOR = 1.74; 95% CI: 1.13–2.67), sneezing (AOR = 1.68; 95% CI: 1.02–2.76), sputum production (AOR = 1.91; 95% CI: 1.15–3.19), headache/dizziness (AOR = 1.73; 95% CI: 1.04–2.87), and muscle soreness (AOR = 2.33; 95% CI: 1.13–4.80). In contrast, there were lower odds of experiencing abdominal pain (AOR = 0.49; 95% CI: 0.25–0.94) and diarrhea (AOR = 0.37; 95% CI: 0.17–0.78) in children who had received vaccination during the post-COVID-19 phase. Conclusions: This study revealed clinical features and vaccination effects in PASC children in Taiwan. Vaccination may reduce some gastrointestinal symptoms in the post-COVID-19 phase.

Original languageEnglish
Article number910
JournalVaccines
Volume12
Issue number8
DOIs
Publication statusPublished - 2024 Aug

All Science Journal Classification (ASJC) codes

  • Immunology
  • Pharmacology
  • Drug Discovery
  • Infectious Diseases
  • Pharmacology (medical)

Cite this